Cargando…
Novel Complex of PD-L1 Aptamer and Holliday Junction Enhances Antitumor Efficacy in Vivo
Blocking the PD-1/PD-L1 pathway can diminish immunosuppression and enhance anticancer immunity. PD-1/PD-L1 blockade can be realized by aptamers, which have good biocompatibility and can be synthesized in quantity economically. For in vivo applications, aptamers need to evade renal clearance and nucl...
Autores principales: | Li, Ting, Yao, Fengjiao, An, Yacong, Li, Xundou, Duan, Jinhong, Yang, Xian-Da |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7921949/ https://www.ncbi.nlm.nih.gov/pubmed/33670583 http://dx.doi.org/10.3390/molecules26041067 |
Ejemplares similares
-
Targeted Therapy of Colon Cancer by Aptamer-Guided Holliday Junctions Loaded with Doxorubicin
por: Yao, Fengjiao, et al.
Publicado: (2020) -
Novel Complex of PD-L1 Aptamer and Albumin Enhances Antitumor Efficacy In Vivo
por: An, Yacong, et al.
Publicado: (2022) -
Novel Nanotherapeutics for Cancer Immunotherapy by PD-L1-Aptamer-Functionalized and Fexofenadine-Loaded Albumin Nanoparticles
por: Lai, Xialian, et al.
Publicado: (2023) -
Selection of a novel DNA aptamer against OFA/iLRP for targeted delivery of doxorubicin to AML cells
por: An, Yacong, et al.
Publicado: (2019) -
Novel Bispecific Aptamer Enhances Immune Cytotoxicity Against MUC1-Positive Tumor Cells by MUC1-CD16 Dual Targeting
por: Li, Zhaoyi, et al.
Publicado: (2019)